MERUS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.26 USD | +2.54% |
|
+7.35% | +108.22% |
| Jul. 08 | Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate | MT |
| Jul. 08 | Merus Initiates Mid-stage Study of Colorectal Cancer Combination Therapy | MT |
Chart calendar Merus N.V.
25ce48127b6a99c48414f5f4a27c9b4.XjGS9UhCV3OwXOfNUYkOuPO3WZK_uXyBhUoSRzyT5Ic.a33KuywuDz_gOIaFJL1E7crxGqSPzAXv7H9LInvRl_ZsR_mqHjYWA_k0jA~2750106e763278134800620e1fe05518
Upcoming events on Merus N.V.
Past events on Merus N.V.
| 2024-06-05 11:00 am | Jefferies Global Healthcare Conference |
| 2024-06-03 02:30 pm | American Society of Clinical Oncology Meeting - Abstract No: 8583 |
| 2024-06-03 09:00 am | American Society of Clinical Oncology Meeting - Abstract No: 6014 |
| 2024-06-02 12:30 pm | American Society of Clinical Oncology Meeting - Abstract No: 2520 |
| 2024-05-28 08:00 am | Petosemtamab in Combination with Pembrolizumab Phase 1/2 Trial Update Call |
| 2024-05-08 04:15 pm | Q1 2024 Earnings Release |
| 2024-05-07 09:00 am | Annual General Meeting |
| 2024-04-10 08:45 am | Needham Healthcare Conference |
| 2024-04-08 12:00 pm | American Association for Cancer Research Meeting - Abstract No : 1903 |
| 2024-03-11 12:00 pm | Leerink Partners Global Biopharma Conference |
| 2024-02-28 04:15 pm | Q4 2023 Earnings Release |
| 2024-02-22 09:00 am | Citi Oncology Leadership Summit |
| 2024-02-07 02:30 pm | Guggenheim Healthcare Talks Biotechnology Conference |
| 2023-12-03 04:50 am | European Society for Medical Oncology Congress - Poster Number: #362P |
| 2023-12-02 08:40 pm | European Society for Medical Oncology Congress - Poster Number: #516MO |
| 2023-12-02 04:50 am | European Society for Medical Oncology Congress - Presentation Number #: 362P |
| 2023-12-02 04:50 am | European Society for Medical Oncology Congress - Poster Number: 595P# |
| 2023-11-30 | European Society for Medical Oncology Congress |
| 2023-11-27 08:00 am | Investor Meeting |
| 2023-11-14 01:15 pm | Stifel Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 31,1 32,2 -3.35% | 29,9 28,5 5.03% | 49,1 46,2 6.22% | 41,6 40,1 3.82% | 43,9 45,1 -2.57% | 41,0 |
|
EBITDA Million USD | Released Forecast Spread | -57,5 -62,6 8.17% | 0,00 0,00 - | -88,7 -91,6 3.13% | -159 -152 -4.89% | -154 -152 -1.5% | -195 |
|
EBIT Million USD | Released Forecast Spread | -58,7 -50,5 -16.04% | -75,9 -72,8 -4.22% | -90,0 -93,3 3.61% | -160 -151 -6.28% | -157 -151 -3.4% | -194 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -55,0 -42,4 -29.52% | -85,0 -74,9 -13.46% | -66,6 -80,1 16.87% | -130 -89,1 -46.24% | -152 -133 -13.82% | -164 |
|
Net income Million USD | Released Forecast Spread | -55,2 -42,8 -28.85% | -85,5 -75,2 -13.74% | -66,8 -78,8 15.16% | -131 -89,3 -46.88% | -155 -133 -16.52% | -175 |
|
EPS USD | Released Forecast Spread | -2,28 -1,73 -31.78% | -2,92 -2,64 -10.79% | -1,73 -2,09 17.28% | -2,92 -2,09 -39.98% | -3,00 -2,63 -13.96% | -2,87 |
| Announcement Date | 12/03/20 | 16/03/21 | 28/02/22 | 28/02/23 | 28/02/24 | - |
Quarterly results
| Fiscal Period | December | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 11,7 9,37 24.43% | 12,7 10,4 21.42% | 6,58 11,0 -40.15% | 10,7 9,70 9.94% | 13,5 11,3 19.55% | 10,5 11,4 -7.83% | 11,0 10,4 5.97% | 8,94 10,1 -11.39% | 7,89 9,10 -13.31% | 8,39 | 8,68 | 16,0 | 5,26 | 4,17 |
|
EBITDA Million USD | Released Forecast Spread | -47,0 -42,9 -9.42% | -47,4 | -46,7 | -47,6 | -48,2 | |||||||||
|
EBIT Million USD | Released Forecast Spread | -27,1 -28,3 4.48% | -31,1 -28,1 -10.77% | -48,2 -33,1 -45.74% | -53,7 -44,3 -21.07% | -36,8 -49,4 25.54% | -33,9 -44,0 22.95% | -38,4 -38,9 1.32% | -47,5 -41,9 -13.37% | -46,8 -47,9 2.2% | -48,7 | -51,1 | -45,9 | -59,3 | -62,4 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -18,8 -27,1 30.8% | -5,58 -27,2 79.5% | -24,3 -29,0 16.26% | -81,6 -40,4 -101.79% | -40,2 -46,8 14.19% | -30,5 -41,1 25.65% | -21,9 -36,0 39.22% | -59,1 -40,7 -45.21% | -33,4 -44,4 24.83% | -44,6 | -44,8 | -39,2 | -49,6 | -53,5 |
|
Net income Million USD | Released Forecast Spread | -18,9 -27,7 31.71% | -5,71 -28,4 79.88% | -24,6 -28,5 13.63% | -82,0 -40,1 -104.24% | -39,7 -47,4 16.17% | -32,0 -40,9 21.69% | -23,0 -35,8 35.69% | -60,2 -38,8 -55.07% | -34,5 -45,0 23.48% | -45,7 | -47,8 | -45,7 | -55,4 | -58,6 |
|
EPS USD | Released Forecast Spread | -0,43 -0,65 33.55% | -0,13 -0,61 78.84% | -0,53 -0,61 13.65% | -1,81 -0,85 -113.49% | -0,86 -1,03 16.86% | -0,66 -0,87 24.29% | -0,43 -0,70 38.34% | -1,09 -0,70 -54.95% | -0,59 -0,79 25.49% | -0,76 | -0,76 | -0,73 | -0,81 | -0,83 |
| Announcement Date | 09/05/22 | 08/08/22 | 03/11/22 | 28/02/23 | 04/05/23 | 07/08/23 | 02/11/23 | 28/02/24 | 08/05/24 | - | - | - | - | - |
More events
Past sector events for Merus N.V.
| 2024-07-11 04:00 pm | NURIX THERAPEUTICS, INC.: Q2 2024 Earnings Release |
| 2024-07-04 | PHARMAESSENTIA CORPORATION: June 2024 Sales and Revenue Release |
| 2024-06-05 03:51 am | PHARMAESSENTIA CORPORATION: May 2024 Sales and Revenue Release |
| 2024-05-17 07:00 am | AUTOLUS THERAPEUTICS PLC: Q1 2024 Earnings Release |
| 2024-05-16 07:46 am | BIOCON LIMITED: Q4 2024 Earnings Release |
| 2024-05-16 01:00 am | ZEALAND PHARMA A/S: Q1 2024 Earnings Release |
| 2024-05-15 | LIGACHEM BIOSCIENCES INC.: Q1 2024 Earnings Release |
| 2024-05-15 08:05 am | THIRD HARMONIC BIO, INC.: Q1 2024 Earnings Release |
| 2024-05-15 07:00 am | CABALETTA BIO, INC.: Q1 2024 Earnings Release |
| 2024-05-14 | TAIMED BIOLOGICS INC.: Q1 2024 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- MRUS Stock
- Calendar Merus N.V.
